An observational study in Coronary Artery Disease and Microvascular Dysfunction, sponsored by Johannes Gutenberg University Mainz. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Johannes Gutenberg University Mainz · Observational
Primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in Mainz. Following amendment of the procol, this study will also include patients who received an Aborb bioresorbable scaffold for the therapy of de novo stenoses.
Patients included in the registry will be contacted by telephone at 3,6,9, 12 months and 2, 5, 10 years after the procedure. In case coronary slow flow is shown at the index procedure, 39ml of blood will be drawn for further studies.
According to the regulations of the Province Rheinland-Pfalz, national law, and with the approval of the Ethic commission of the Landesärztekammer Rheinland Pfalz, patients (n=1000) will also be retrospectively entered in the database in an anonymous way. For these patients, no specific study procedure is foreseen and the MICAT database will be only used as a platform (database of anonymous data collected during routine clinical practice).
5,596 studies on the registry are indexed under Coronary Artery Disease; 955 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 336 across 1,946 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Johannes Gutenberg University Mainz is the lead sponsor of 153 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with clinical indication for coronary angiography.
Exclusion Criteria:
Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
Other: observational only- no intervention
Major adverse cardiovascular events
Incidence of major adverse events (death, death of cardiac cause, TLR - target lesion revascularization, MI)
Time frame: baseline to 10 years
Individual endpoints
Each individual endpoint of the MACE previously described
Time frame: baseline to 10 years
Other cardiovascular endpoints
TVR - target vessel revascularization, re-hospitalization, change in medications.
Time frame: baseline to 10 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johannes Gutenberg University Mainz